c 1311 has been researched along with Benign Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourbouloux, E; Campone, M; Capizzi, R; Drouin, M; Fumoleau, P; Grieshaber, C; Isambert, N; Loadman, P; Major, A; Yin, W | 1 |
| Comijn, E; De Marco, C; Peters, GJ; Tesei, A; Zaffaroni, N; Zoli, W | 1 |
1 trial(s) available for c 1311 and Benign Neoplasms
| Article | Year |
|---|---|
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Aminoacridines; Antineoplastic Agents; Biological Availability; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2010 |
1 other study(ies) available for c 1311 and Benign Neoplasms
| Article | Year |
|---|---|
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines.
Topics: Aminoacridines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin B; Cyclin B1; Doxorubicin; Drug Therapy, Combination; G2 Phase; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Paclitaxel; Rhodamines; Tumor Cells, Cultured | 2007 |